Your thoughts on Clinuvel pharmaceutical (CUV)
Hi James, I am interested in hearing your thoughts on CUV. It was once a $40/- stock but now has dropped 35%. They are doing various clinical trials. Do you think it is still worth holding it? Thanks.
The Latest Q&A
Answer
Hi Shernavaz,
This Australian company focused on dermatology related pharmaceutical products is a great example of the challenges and volatility that can be experienced in bio tech stocks. While this is a ‘proper business’ with earnings and a pipeline of products, I have never actually managed to make money out of bio techs over the years, so I tend to stay clear of them. Imugene (IMU) is one Harry has backed and I have a client that owns a lot of shares in IMU, if it does 20% of what he believes it will do, it will be an amazing success. For me , I don’t think I have an edge in the space sorry.
